Aescap group and Patrick Krol report ProQR (PRQR) shareholdings

Rhea-AI Filing Summary

ProQR Therapeutics N.V. has a shareholder group of Netherlands-based entities and portfolio manager Patrick Johan Hendrik Krol reporting holdings of its ordinary shares on a Schedule 13G/A, based on 141,121,476 ordinary shares outstanding.

Aescap Life Sciences directly holds 4,156,878 shares, or about 2.95% of the class, and Aescap Genetics holds 1,310,271 shares, or 0.93%. Inspirational Visions holds 35,411 shares, or 0.03%. Privium Fund Management B.V., as fund manager of Aescap Life Sciences and Aescap Genetics, may be deemed to beneficially own 5,467,149 shares, or 3.87%.

Through his roles with these entities and a direct holding of 26,302 shares, Krol may be deemed to beneficially own 5,528,862 ProQR shares, or approximately 3.92% of the outstanding ordinary shares. All reporting persons are described as having sole voting and sole dispositive power over their respective positions, with no shared authority reported.

Key Figures

Aescap Life Sciences holdings: 4,156,878 shares Privium beneficial ownership: 5,467,149 shares Aescap Genetics holdings: 1,310,271 shares +3 more

6 metrics

Aescap Life Sciences holdings 4,156,878 shares Direct holdings of ProQR ordinary shares; approximately 2.95% of the class

Privium beneficial ownership 5,467,149 shares Beneficially owned through Aescap Life Sciences and Aescap Genetics; about 3.87% of shares outstanding

Aescap Genetics holdings 1,310,271 shares Direct holdings of ProQR ordinary shares; approximately 0.93% of the class

Inspirational Visions holdings 35,411 shares Direct holdings of ProQR ordinary shares; approximately 0.03% of the class

Patrick J.H. Krol beneficial ownership 5,528,862 shares Includes direct and indirect holdings; approximately 3.92% of ProQR ordinary shares

Shares outstanding baseline 141,121,476 shares Ordinary shares outstanding used to calculate ownership percentages

Key Terms

beneficially owned, sole voting power, sole dispositive power, Schedule 13G/A, +1 more

5 terms

beneficially owned financial

"As of the date of this report, Aescap Life Sciences directly held 4,156,878 Shares"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power financial

"Aescap Life Sciences: 4,156,878 Privium: 5,467,149 ... Sole power to vote"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"Sole power to dispose or to direct the disposition of: Aescap Life Sciences"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Schedule 13G/A regulatory

"The disclosure is made on a Schedule 13G/A"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Joint Filing Agreement regulatory

"Exhibit 99.1: Joint Filing Agreement (filed herewith)"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/15/2026 - 11:55 AM Accepted by SEC EDGAR 07/15/2026 - 11:54 AM Learn about SEC filing dates

FAQ

What stake in ProQR (PRQR) does Aescap Life Sciences report?

Aescap Life Sciences directly holds 4,156,878 ProQR ordinary shares, representing about 2.95% of the class. This percentage is calculated using 141,121,476 ordinary shares outstanding as the reference share count.

How much of ProQR (PRQR) does Privium Fund Management B.V. beneficially own?

Privium Fund Management B.V. may be deemed to beneficially own 5,467,149 ProQR shares, or approximately 3.87% of the outstanding ordinary shares, through its role as fund manager for Aescap Life Sciences and Aescap Genetics.

What is Patrick Johan Hendrik Krol’s beneficial ownership in ProQR (PRQR)?

Patrick Johan Hendrik Krol may be deemed to beneficially own 5,528,862 ProQR shares, or about 3.92% of the class. This includes his direct holding of 26,302 shares and indirect holdings through Aescap Life Sciences, Aescap Genetics and Inspirational Visions.

What ProQR (PRQR) share count is used to calculate ownership percentages?

Ownership percentages are calculated using 141,121,476 ProQR ordinary shares outstanding. Each reporting person’s percentage, such as Aescap Life Sciences’ 2.95% and Privium’s 3.87%, is stated as a fraction of this total share count.

Which reporting persons are named in the ProQR (PRQR) Schedule 13G/A?

The reporting persons are Stichting Aescap Life Sciences, Privium Fund Management B.V., Stichting Aescap Genetics, Inspirational Visions BV, and Patrick Johan Hendrik Krol. Each is described as having citizenship or organization in the Netherlands.

Do the ProQR (PRQR) reporting persons have shared voting or dispositive power?

No shared authority is reported. Each of Aescap Life Sciences, Privium, Aescap Genetics, Inspirational Visions and Patrick Krol is listed with sole voting power and sole dispositive power over the ProQR shares attributed to that reporting person.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

ProQR Therapeutics N.V.

(Name of Issuer)

Ordinary Shares, nominal value EUR0.04 per share

(Title of Class of Securities)

N71542109

(CUSIP Number)

07/15/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): N71542109

1

Names of Reporting Persons

STICHTING AESCAP LIFE SCIENCES

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NETHERLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,156,878.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,156,878.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,156,878.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.95 %

12

Type of Reporting Person (See Instructions)

FI

Comment for Type of Reporting Person: (1) Based upon 141,121,476 ordinary shares outstanding

SCHEDULE 13G

CUSIP Number(s): N71542109

1

Names of Reporting Persons

PRIVIUM FUND MANAGEMENT B.V.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NETHERLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,467,149.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,467,149.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,467,149.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.87 %

12

Type of Reporting Person (See Instructions)

FI

Comment for Type of Reporting Person: (1) Based upon 141,121,476 ordinary shares outstanding

SCHEDULE 13G

CUSIP Number(s): N71542109

1

Names of Reporting Persons

STICHTING AESCAP GENETICS

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NETHERLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,310,271.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,310,271.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,310,271.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.93 %

12

Type of Reporting Person (See Instructions)

FI

Comment for Type of Reporting Person: (1) Based upon 141,121,476 ordinary shares outstanding

SCHEDULE 13G

CUSIP Number(s): N71542109

1

Names of Reporting Persons

INSPIRATIONAL VISIONS B.V.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NETHERLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 35,411.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 35,411.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

35,411.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.03 %

12

Type of Reporting Person (See Instructions)

FI

Comment for Type of Reporting Person: (1) Based upon 141,121,476 ordinary shares outstanding

SCHEDULE 13G

CUSIP Number(s): N71542109

1

Names of Reporting Persons

PATRICK JOHAN HENDRIK KROL

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NETHERLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,528,862.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,528,862.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,528,862.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

FI

Comment for Type of Reporting Person: (1) Based upon 141,121,476 ordinary shares outstanding

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ProQR Therapeutics N.V.
(b)	Address of issuer's principal executive offices: Zernikedreef 9, Leiden, The Netherlands CK 2333
Item 2.
(a)	Name of person filing: (i) Stichting Aescap Life Sciences ("Aescap Life Sciences") (ii) Privium Fund Management B.V. ("Privium"), as the fund manager of Aescap Life Sciences (iii) Stichting Aescap Genetics ("Aescap Genetics") (iv) Inspirational Visions BV ("Inspirational Visions") (v) Patrick Johan Hendrik Krol ("Krol"), the portfolio manager for Privium regarding Aescap Life Sciences and Aescap Genetics and the managing director of Inspirational Visions The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
(b)	Address or principal business office or, if none, residence: The principal business address of each of Aescap Life Sciences, Privium, Aescap Genetics and Krol is: Gustav Mahlerplein 3 1082 MS Amsterdam The Netherlands The principal business address of Inspirational Visions is: A.J. Ernststraat 595-C 1082 LN Amsterdam The Netherlands
(c)	Citizenship: The citizenship of each of the Reporting Persons is the Netherlands.
(d)	Title of class of securities: Ordinary Shares, nominal value EUR0.04 per share
(e)	CUSIP No.: N71542109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As its Fund Manager, the Shares held by Aescap Life Sciences may be deemed to be beneficially owned by Privium. In addition, as its Fund Manager, the Shares held by Aescap Genetics may be deemed to be beneficially owned by Privium. As the portfolio manager of Privium, Krol may be deemed to beneficially own the Shares held by Aescap Life Sciences and Aescap Genetics. In addition, as the managing director of Inspirational Visions, Krol may be deemed to beneficially own the Shares held by Inspirational Visions. As of the date of this report, Aescap Life Sciences directly held 4,156,878 Shares. As of the date of this report, Aescap Genetics directly held 1,310,271 Shares. As of the date of this report, Inspirational Visions directly held 35,411 Shares. As of the date of this report, Krol directly held 26,302 Shares.
(b)	Percent of class: Aescap Life Sciences may be deemed the beneficial owner of approximately 2.95% of the Shares outstanding. Privium may be deemed the beneficial owner of approximately 3.87% of the Shares outstanding. Aescap Genetics may be deemed the beneficial owner of approximately 0.93% of the Shares outstanding. Inspirational Visions may be deemed the beneficial owner of approximately 0.03% of the Shares outstanding. Krol may be deemed the beneficial owner of approximately 3.92% of the Shares outstanding.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Aescap Life Sciences: 4,156,878 Privium: 5,467,149 Aescap Genetics: 1,310,271 Inspirational Visions: 35,411 Krol: 5,528,862
	(ii) Shared power to vote or to direct the vote: Aescap Life Sciences: 0 Privium: 0 Aescap Genetics: 0 Inspirational Visions: 0 Krol: 0
	(iii) Sole power to dispose or to direct the disposition of: Aescap Life Sciences: 4,156,878 Privium: 5,467,149 Aescap Genetics: 1,310,271 Inspirational Visions: 35,411 Krol: 5,528,862
	(iv) Shared power to dispose or to direct the disposition of: Aescap Life Sciences: 0 Privium: 0 Aescap Genetics: 0 Inspirational Visions: 0 Krol: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

STICHTING AESCAP LIFE SCIENCES

Signature:	/s/ P.J.H. Krol
Name/Title:	P.J.H. Krol, Portfolio Manager of Privium Fund Management B.V., its Fund Manager
Date:	07/15/2026

PRIVIUM FUND MANAGEMENT B.V.

Signature:	/s/ P.J.H. Krol
Name/Title:	P.J.H. Krol, Portfolio Manager
Date:	07/15/2026

STICHTING AESCAP GENETICS

Signature:	/s/ P.J.H. Krol
Name/Title:	P.J.H. Krol, Portfolio Manager of Privium Fund Management B.V., its Fund Manager
Date:	07/15/2026

INSPIRATIONAL VISIONS B.V.

Signature:	/s/ P.J.H. Krol
Name/Title:	P.J.H. Krol, Managing Director
Date:	07/15/2026

PATRICK JOHAN HENDRIK KROL

Signature:	/s/ P.J.H. Krol
Name/Title:	P.J.H. Krol
Date:	07/15/2026

Exhibit Information

Exhibit 99.1: Joint Filing Agreement (filed herewith).